Professor Dingwei Ye and Professor Xiaojie Bian: Breaking Through Treatment Challenges in mCRPC with Sacituzumab Tirumotecan Plus Immunotherapy for Durable Survival Benefits

Professor Dingwei Ye and Professor Xiaojie Bian: Breaking Through Treatment Challenges in mCRPC with Sacituzumab Tirumotecan Plus Immunotherapy for Durable Survival Benefits

Patients with metastatic castration-resistant prostate cancer (mCRPC) who experience disease progression following novel endocrine therapy have very limited treatment options, presenting a major clinical challenge. In recent years, China has made substantial advances in innovative drug development, continuously reshaping treatment strategies. Novel TROP2 antibody-drug conjugates (ADCs), represented by sacituzumab tirumotecan, have demonstrated promising potential in prostate cancer. When combined with immunotherapy, the regimen achieved an overall objective response rate (ORR) of 47.4%, a disease control rate (DCR) of 89.5%, a duration of response (DoR) of 24.7 months, and a PSA50 response rate of 39.1% in the overall population. Median radiographic progression-free survival (rPFS) was 13.1 months, and median overall survival (OS) reached 22.8 months, potentially opening up a new treatment pathway for patients with mCRPC.
Professor Benkang Shi: Advancing Standardization and Precision—Challenges, Pathways, and Future Directions in Prostate Cancer Care in China | Pujiang Prostate Cancer Academic Conference

Professor Benkang Shi: Advancing Standardization and Precision—Challenges, Pathways, and Future Directions in Prostate Cancer Care in China | Pujiang Prostate Cancer Academic Conference

The Pujiang Prostate Cancer Academic Conference was recently held in Shanghai. Under the theme “Standardization, Precision, Chinese Innovation, and Global Collaboration,” the conference provided a high-level platform for academic exchange, focusing on key topics including early screening and precision diagnosis of prostate cancer, optimization of local treatment strategies, innovation in advanced disease management, and the development of comprehensive care systems. By fostering deeper integration between clinical practice and cutting-edge research, the conference aimed to further advance the standard of prostate cancer care in China.
Prof. Wang Liang: How to Precisely Choose Between Autologous and Allogeneic Transplantation for First-Line Consolidation in Peripheral T-Cell Lymphoma? | 2026 Cross-Strait Hematology Conference

Prof. Wang Liang: How to Precisely Choose Between Autologous and Allogeneic Transplantation for First-Line Consolidation in Peripheral T-Cell Lymphoma? | 2026 Cross-Strait Hematology Conference

Peripheral T-cell lymphoma (PTCL) is highly heterogeneous and associated with poor prognosis, making the selection of an optimal first-line consolidation strategy a persistent clinical challenge. How can clinicians pursue deeper remission while balancing the graft-versus-lymphoma effect against the risk of non-relapse mortality? This lies at the heart of the clinical decision between autologous and allogeneic hematopoietic stem cell transplantation. During the 2026 Cross-Strait Hematology Conference, Prof. Wang Liang from Beijing Tongren Hospital, Capital Medical University, spoke with Oncology Frontier – Hematology Frontier about the positioning and selection of autologous versus allogeneic transplantation for first-line consolidation in PTCL based on evidence from evidence-based medicine. He also discussed prospectively how cellular immunotherapy may reshape future treatment paradigms.
2026 Pujiang Urological Oncology Academic Conference丨Professor Hailiang Zhang: From Mechanisms of Immunotherapy Resistance to Precision Risk Stratification and Treatment—New Insights from the “Eggshell Structure” Discovered Through Spatial Multi-Omics and Advances in Systemic Therapy for Urological Tumors

2026 Pujiang Urological Oncology Academic Conference丨Professor Hailiang Zhang: From Mechanisms of Immunotherapy Resistance to Precision Risk Stratification and Treatment—New Insights from the “Eggshell Structure” Discovered Through Spatial Multi-Omics and Advances in Systemic Therapy for Urological Tumors

Systemic therapy for urological tumors is undergoing a profound transformation, shifting from empiric treatment toward mechanism-driven, precision-based risk stratification and whole-course management. In clear cell renal cell carcinoma (ccRCC), the immune-excluded tumor microenvironment is an important factor influencing the efficacy of immune checkpoint inhibitors. In urothelial carcinoma, antibody-drug conjugates (ADCs) combined with immunotherapy are moving beyond first-line treatment for advanced disease and increasingly being explored in the perioperative setting. For von Hippel-Lindau (VHL) syndrome, standardized management of this rare disease and the application of HIF-2α inhibitors are also reshaping traditional approaches to multi-organ intervention. As new mechanisms and therapeutic strategies continue to expand the boundaries of treatment, identifying patients most likely to benefit, dynamically evaluating treatment response, and appropriately transitioning patients with disease progression to subsequent therapies have become key questions in clinical practice. At the 2026 Pujiang Urological Oncology Academic Conference, Oncology Frontier – Urology Frontier invited Professor Hailiang Zhang of Huadong Hospital Affiliated to Fudan University for an exclusive interview. Professor Zhang discussed the mechanisms of immunotherapy resistance in renal cell carcinoma, advances in the diagnosis and treatment of urothelial carcinoma and VHL syndrome, as well as precision treatment selection and whole-course management.
Professor Yongmei Yin: Advancing Precision Oncology from Concept to Clinical Practice — Key Insights from the 2026 “Renyi” Clinical Research Conference on Innovative Anticancer Drugs

Professor Yongmei Yin: Advancing Precision Oncology from Concept to Clinical Practice — Key Insights from the 2026 “Renyi” Clinical Research Conference on Innovative Anticancer Drugs

From July 31 to August 2, 2026, the 2026 “Renyi” Clinical Research Conference on Innovative Anticancer Drugs was held in Nanjing. The conference was part of the academic events celebrating the 90th anniversary of Jiangsu Province Hospital (the First Affiliated Hospital of Nanjing Medical University and Jiangsu Women and Children’s Medical Center). Under the theme “Innovating Drug Development, Driving Translational Research, Celebrating 90 Years of Medical Excellence, and Embarking on a New Journey,” the conference focused on the full development pathway of clinical research on innovative anticancer drugs.
10th Yunling Breast Cancer Conference | Professor Jianyun Nie: Standardization as the Foundation for Regional Diagnosis and Treatment, Precision Driving the Evolution of Breast Surgery

10th Yunling Breast Cancer Conference | Professor Jianyun Nie: Standardization as the Foundation for Regional Diagnosis and Treatment, Precision Driving the Evolution of Breast Surgery

Since its establishment in 2016, the Yunling Breast Cancer Conference has been successfully held for ten consecutive editions. It has evolved from a learning and exchange platform initially serving breast cancer professionals in Yunnan Province into a major academic meeting with influence across Southwest China and nationally. The 10th Yunling Breast Cancer Conference was held in Kunming from August 21–23, 2026. During the conference, Professor Jianyun Nie, Vice President of Yunnan Cancer Hospital, reviewed the ten-year development of the conference and shared his perspectives on standardized breast cancer diagnosis and treatment in the region, capacity building in primary healthcare institutions, and the precision-driven evolution of breast surgery.
Professor Ma Jun: Current Landscape and Future Perspectives of Cell Therapy Amid the CGT Wave | 2026 Cross-Strait Hematology Academic Conference

Professor Ma Jun: Current Landscape and Future Perspectives of Cell Therapy Amid the CGT Wave | 2026 Cross-Strait Hematology Academic Conference

In the golden autumn season, experts and scholars gathered in Zhuhai. The 2026 Cross-Strait Hematology Academic Conference was held in Zhuhai, Guangdong, from August 21–22. Hematology experts from both sides of the Taiwan Strait, as well as Hong Kong and Macao, came together to discuss cutting-edge developments, clinical practice, and innovations in nursing. During the conference, Oncology Frontier – Hematology Frontier interviewed Professor Ma Jun of the Harbin Institute of Hematology and Oncology, who shared his perspectives on the rapidly developing field of cell and gene therapy (CGT). He reviewed the global and domestic landscape of approved cell therapy products, real-world clinical data, and China's strengths in innovation, while also discussing challenges related to original research and development, standardization, treatment accessibility, and the future of CGT.
Professor Hou Hsin-An: Deepening Cross-Strait Hematology Exchange and Exploring New Pathways for Precision Diagnosis and Treatment | 2026 Cross-Strait Hematology Conference

Professor Hou Hsin-An: Deepening Cross-Strait Hematology Exchange and Exploring New Pathways for Precision Diagnosis and Treatment | 2026 Cross-Strait Hematology Conference

In the golden autumn season, the Greater Bay Area comes alive, as colleagues from across the mountains and seas come together. The 2026 Cross-Strait Hematology Conference was held with great success in Zhuhai, Guangdong, from August 21–22. Hematology experts and scholars from mainland China, Taiwan, Hong Kong, and Macao gathered to engage in in-depth discussions on topics including cutting-edge developments in the field, clinical practice, and nursing innovation. During the conference, Professor Hou Hsin-An, Conference Chair and President of the Taiwan Society of Hematology, spoke with the media. Drawing on the strong foundation and broad prospects for hematology exchange across the Taiwan Strait, Professor Hou shared forward-looking perspectives on key topics including deepening academic exchange and collaborative cooperation, advancing precision diagnosis and treatment of hematologic diseases, and promoting the development and growth of young hematology professionals.
Professor Lanping Xu: Joining Forces in the Greater Bay Area to Build a New Platform for Hematology Exchange Across the Mainland, Taiwan, Hong Kong, and Macao | 2026 Cross-Strait Hematology Conference%

Professor Lanping Xu: Joining Forces in the Greater Bay Area to Build a New Platform for Hematology Exchange Across the Mainland, Taiwan, Hong Kong, and Macao | 2026 Cross-Strait Hematology Conference%

In the golden autumn season, colleagues from across the mountains and seas came together. The 2026 Cross-Strait Hematology Conference was held in Zhuhai, Guangdong, on August 21–22, bringing together hematology experts and scholars from the Chinese mainland, Taiwan, Hong Kong, and Macao to engage in in-depth discussions on advances in the field, clinical practice, and nursing innovation. During the conference, Professor Lanping Xu of Peking University People's Hospital, Chair of the Hematology Committee of the Cross-Strait Medical and Health Exchange Association and Conference Chair, spoke with the media about the conference agenda, complementary strengths in hematopoietic stem cell transplantation across the mainland and Taiwan, and the long-term value of the academic platform.
The 14th Lu Daopei Hematology Forum丨Professor Huili Zhu: Evidence-Based Updates and Precision Prevention and Control — A Clinical Interpretation of the 7th Edition of the Guidelines for Invasive Fungal Disease in Hematologic Disorders

The 14th Lu Daopei Hematology Forum丨Professor Huili Zhu: Evidence-Based Updates and Precision Prevention and Control — A Clinical Interpretation of the 7th Edition of the Guidelines for Invasive Fungal Disease in Hematologic Disorders

Bringing together leading experts in the field, the 14th Lu Daopei Hematology Forum opened on August 21, 2026, at Hebei Yanda Lu Daopei Hospital. Building on 14 years of academic development, this year’s conference focused on cutting-edge topics including hematopoietic stem cell transplantation, cellular immunotherapy, and precision diagnosis and treatment of hematologic disorders. The conference brought together leading experts and scholars from across China to discuss the future development of hematology and served as an important platform for advancing the diagnosis and treatment of hematologic diseases in China. During the conference, Oncology Frontier – Hematology Frontier invited Professor Huili Zhu from Lu Daopei Hospital to share her insights into the updated 7th edition of the guidelines for invasive fungal disease (IFD) in patients with hematologic disorders, focusing on the background of the update, key changes, and strategies for clinical implementation.